Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Frontline”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06592170
What this trial is testing

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Who this might be right for
Lymphoma
The First Hospital of Jilin University 35
Testing effectiveness (Phase 2)UnknownNCT05963347
What this trial is testing

Go-CHOP as the Frontline Therapy for PTCL

Who this might be right for
Peripheral T Cell Lymphoma
Henan Cancer Hospital 45
Not applicableEnded earlyNCT04767958
What this trial is testing

The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing

Who this might be right for
Covid19
Ottawa Heart Institute Research Corporation 89
Large-scale testing (Phase 3)UnknownNCT05822050
What this trial is testing

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

Who this might be right for
PTCL Patients Who Achieved Complete Response From Frontline Treatment
The First Hospital of Jilin University 20
Testing effectiveness (Phase 2)Ended earlyNCT01018069
What this trial is testing

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Who this might be right for
Leukemia
Aegera Therapeutics 60
Testing effectiveness (Phase 2)Study completedNCT00794820
What this trial is testing

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Who this might be right for
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center 66
Early research (Phase 1)Ended earlyNCT02819999
What this trial is testing

Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
AbbVie 28
Not applicableStudy completedNCT05906095
What this trial is testing

Pragmatic Trial to Increase Quality of Care in State Veterans Homes

Who this might be right for
Long-Term CareAccidental Falls
VA Office of Research and Development 574
Testing effectiveness (Phase 2)Study completedNCT01643408
What this trial is testing

Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Who this might be right for
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Jazz Pharmaceuticals 30
Large-scale testing (Phase 3)Study completedNCT00656448
What this trial is testing

Trial of Procrit vs. No Procrit in AML and High Risk MDS

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
M.D. Anderson Cancer Center 51
Testing effectiveness (Phase 2)Looking for participantsNCT05183984
What this trial is testing

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 390
Testing effectiveness (Phase 2)UnknownNCT03226249
What this trial is testing

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaLymphocyte-Depleted Classical Hodgkin LymphomaLymphocyte-Rich Classical Hodgkin Lymphoma+2 more
Northwestern University 30
Testing effectiveness (Phase 2)Study completedNCT00381004
What this trial is testing

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05455996
What this trial is testing

MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders

Who this might be right for
Post-Traumatic Stress DisorderAdjustment Disorders
Nautilus Sanctuary 30
Testing effectiveness (Phase 2)UnknownNCT02744768
What this trial is testing

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 60
Not applicableStudy completedNCT05049187
What this trial is testing

Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers

Who this might be right for
Covid19
Tuberculosis Research Centre, India 132
Not applicableUnknownNCT04930133
What this trial is testing

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

Who this might be right for
NSCLC
Seoul St. Mary's Hospital 737
Testing effectiveness (Phase 2)Active Not RecruitingNCT04551131
What this trial is testing

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Who this might be right for
Hemophagocytic Lymphohistiocytosis
St. Jude Children's Research Hospital 10
Not applicableLooking for participantsNCT05831865
What this trial is testing

Frontline of ASCT in High-risk DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
Peking University People's Hospital 175
Testing effectiveness (Phase 2)Active Not RecruitingNCT03319901
What this trial is testing

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Who this might be right for
Leukemia
Dana-Farber Cancer Institute 82
Next Page